RxDoctor Payments DataLook up a doctor →

Bahador Tafazoli, MD

Sleep Medicine · Cullman, ALNPI 1811984149

Payments from drug & device makers

$26,478in general payments, 2019–2025

Across 722 payments — averaging $36.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jazz Pharmaceuticals Inc.$8K
  • Inspire Medical Systems, Inc.$8K
  • Harmony Biosciences LLC$1K
  • Axsome Therapeutics, Inc.$1K
  • GSK$874
  • AstraZeneca$850
  • plus $7K from 39 others

What the payments were for

  • Speaking & faculty fees$5,24020%
  • Travel & lodging$4,46917%
  • Food & beverage$16,50962%
  • Education$2611%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,478 in reported general payments places this provider in the 60th percentile of 28 sleep medicine providers in Alabama.

See all sleep medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$143,479
Medicare patients
712
Services billed
1,576

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XywavSodium,calcium,mag,pot Oxybate36$549,503
SunosiSolriamfetol Hcl27$31,234
DayvigoLemborexant19$6,506
Modafinil70$4,263
Armodafinil61$4,052
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine114$3,254
Ropinirole Hcl128$1,602
Trazodone Hcl173$1,307
Eszopiclone78$671
Pramipexole DihydrochloridePramipexole Di-Hcl68$622
Montelukast Sodium31$524
Fluticasone Propionate35$513
Temazepam79$491
Methylphenidate Hcl23$465
Clonazepam83$428

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Axsome Therapeutics, Inc.Sunosi$1,132$31,23427 claims
Eisai Inc.Dayvigo$16$6,50619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 28 sleep medicine providers in Alabama.

Other sleep medicine in Cullman

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →